- In patients with type 2 diabetes mellitus (T2DM), sodium-glucose co-transporter 2 (SGLT2) inhibitors use decreased alanine aminotransferase [ALT]) level and liver fat, along with the effect of weight loss.
Why this matters
- Nonalcoholic fatty liver disease is common in patients with T2DM.
- SGLT2 inhibitors may become a new option for the treatment of T2DM with NAFLD.
- 6 randomised controlled trials (RCTs; n=309) met eligibility criteria after a search across electronic databases.
- Primary outcomes: change of liver enzymes (ALT and aspartate aminotransferase [AST]) and magnetic resonance imaging-proton density fat fraction (MRI-PDFF).
- Funding: None.
- SGLT2 inhibitors significantly reduced ALT level (weighted mean difference [WMD], −11.05 [95% CI, −19.85 to −2.25] IU/L; P=.01; I2=73%) and MRI-PDFF (WMD, −2.07%; 95% CI, −3.86 to 0.28%; P=.02).
- SGLT2 inhibitors were not associated with a reduction in AST (WMD, −1.11 [95% Cl, −2.39 to 0.17] IU/L; P=.09).
- SGLT2 inhibitors were linked to a reduction in body weight (WMD, −1.62 [95% Cl, −2.02 to -1.23] kg) and visceral fat area (WMD, −19.98 [95% CI, −27.18 to −12.79] cm2; P<.00001 for both>
- Heterogeneity among studies.
- Small sample size and short follow-up.